BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

7:00 PM
Jun 30, 2008
 |  BC Extra  |  Clinical News

Antisense, Teva report ATL/TV1102 meets endpoint

Antisense (ASX:ANP) and Teva (NASDAQ:TEVA) said ATL/TV1102 met the primary endpoint of a significant reduction vs. placebo in the cumulative number of new active lesions on weeks 4, 8 and 12 in a...

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >